Trial · NCT07895771
Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac Arrest
NCT07895771, Not applicable, Recruiting, University Medical Centre Ljubljana
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac Arrest. Trials, record NCT07895771. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895771
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac Arrest
- NCT number
- NCT07895771
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 100 participants, estimated
- Lead sponsor
- University Medical Centre Ljubljana
- Conditions
- Out-of-Hospital Cardiac Arrest, Hypoxic-Ischemic Brain Injury, Post-Cardiac Arrest Syndrome
- Interventions
- Minimal sedation, Standard continuous sedation
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum neuron-specific enolase (NSE) concentration | 72 hours after return of spontaneous circulation (ROSC) | Serum NSE concentration (micrograms/L) measured in the central hospital laboratory by electrochemiluminescence immunoassay; analysed as a continuous variable (log-transformed). |
| Secondary | In-hospital mortality | From hospital admission to hospital discharge, assessed up to 90 days | Death from any cause during the index hospitalization. |
| Secondary | Length of hospital stay | From hospital admission to hospital discharge, assessed up to 90 days | Number of days from hospital admission to hospital discharge. |
| Secondary | Neurological outcome at hospital discharge (Cerebral Performance Category) | At hospital discharge, assessed up to 90 days | Cerebral Performance Category (CPC) scale, range 1-5, where higher scores indicate worse outcome; good outcome defined as CPC 1-2 and poor outcome as CPC 3-5. |
| Secondary | Duration of mechanical ventilation | From ICU admission until successful liberation from mechanical ventilation, assessed up to 30 days | Number of days from start of invasive mechanical ventilation to first successful extubation (24 hours without invasive ventilation) or 24 hours of unassisted breathing via tracheostomy. |
| Secondary | Length of ICU stay | From ICU admission to ICU discharge, assessed up to 30 days | Number of days from ICU admission to ICU discharge (or the day the patient is ready for ICU discharge). |
| Secondary | Area under the curve (AUC) of serum NSE | 24, 48 and 72 hours after ROSC | Area under the time-concentration curve of serum NSE measured at 24, 48 and 72 hours after ROSC. |
| Secondary | Incidence of hyperthermia | First 72 hours after ROSC or until return of consciousness, whichever occurs first | Proportion of patients with at least one episode of core body temperature above 37.5 degrees C (urinary bladder or central venous catheter). |
| Secondary | Incidence of seizures | From randomization to ICU discharge, assessed up to 30 days | Proportion of patients with clinically recognised or EEG-confirmed seizures during ICU treatment. |
| Secondary | Protocol adherence | From randomization to ICU discharge, assessed up to 30 days | Proportion of patients treated fully according to the allocated protocol; reasons for deviations (hyperthermia, seizures, delirium or other acute neurological disorder, haemodynamic instability, technical limitations, physician decision) are recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895771
GET https://conductscience.org/api/trials/v1/NCT07895771/registered